Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad342 ↗Kurz gefasst
Leserbrief in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von William D Shipman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Melanoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Dermatology.
- Pathology, Yale University School of Medicine, New Haven, CT, USA.
Zitieren
APA
Shipman, W. D., Singh, K., Cohen, J. M., Leventhal, J., Damsky, W., & Tomayko, M. M. (2023). Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad342
Vancouver
Shipman WD, Singh K, Cohen JM, Leventhal J, Damsky W, Tomayko MM. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad342
BibTeX
@article{Shipman2023,
author = {Shipman, William D and Singh, Katelyn and Cohen, Jeffery M and Leventhal, Jonathan and Damsky, William and Tomayko, Mary M},
title = {Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad342}
}
EUVIMED